The estimated Net Worth of Tahir Ph.D. Mahmood is at least $836 mil dollars as of 22 November 2023. Dr Mahmood owns over 286,320 units of Applied Molecular Transport stock worth over $126,032 and over the last 4 years he sold AMTI stock worth over $88,857. In addition, he makes $621,009 as Co-Founder e CEO & Director at Applied Molecular Transport.
Dr has made over 8 trades of the Applied Molecular Transport stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 286,320 units of AMTI stock worth $45,811 on 22 November 2023.
The largest trade he's ever made was selling 286,320 units of Applied Molecular Transport stock on 22 November 2023 worth over $45,811. On average, Dr trades about 40,531 units every 55 days since 2021. As of 22 November 2023 he still owns at least 484,738 units of Applied Molecular Transport stock.
You can see the complete history of Dr Mahmood stock trades at the bottom of the page.
Dr. Tahir Mahmood Ph.D. is the Co-Founder, CEO & Director at Applied Molecular Transport.
As the Co-Founder e CEO & Director of Applied Molecular Transport, the total compensation of Dr D at Applied Molecular Transport is $621,009. There are no executives at Applied Molecular Transport getting paid more.
Dr D is 46, he's been the Co-Founder e CEO & Director of Applied Molecular Transport since . There are 7 older and 1 younger executives at Applied Molecular Transport. The oldest executive at Applied Molecular Transport Inc. is Dr. Randall Mrsny Ph.D., 66, who is the Co-Founder, Chief Scientific Officer & Director.
Tahir's mailing address filed with the SEC is AMTI C/O CORPORATION TRUST COMPANY,, TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DE, 19801.
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim, eTahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: